Clinical Trial Update: Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study assessing safety, reactogenicity, and immunogenicity of the Ty800 typhoid vaccine in healthy adults; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Ty800

Snippet

Sponsor: Avant Immunotherapeutics | Conditions: Typhoid Fever | Phase 2 | Status: COMPLETED